GenePeeks Appoints Jeffrey Field as Chief Commercial Officer

GenePeeks Appoints Jeffrey Field as Chief Commercial Officer

–  Industry Leader Joins from Foundation Medicine –

– Brings Commercial Expertise in Genomics, Managed Care to Pre-Conception Risk Prediction Company–

New York and Cambridge, Mass. – September 15, 2015 – GenePeeks, Inc., a genetic information company focused on next-generation disease risk analysis, announced today that Jeffrey Field has joined the company as Chief Commercial Officer. Field will be responsible for leading commercial activities at GenePeeks as the company expands global access to its pre-conception risk prediction products and services.

"The addition of Jeff to the GenePeeks team is an important step in the expansion of our commercial organization," said Anne Morriss, CEO of GenePeeks.  "Jeff's expertise in bringing breakthrough science to market, building high-performance teams and working successfully with managed care organizations make him singularly qualified to lead our commercialization efforts."

GenePeeks digitally combines the DNA information of prospective parents to create "Virtual Progeny" and evaluate their risk for more than 500 recessive genetic diseases.  The company's proprietary technology uses patented informatics to look deep inside a future child's potential genome to uncover disease risk that cannot be seen with alternative screening tools.

"GenePeeks' ability to harness genomic data is transformational," said Field.  "I am thrilled to be joining a company that is uniquely capable of protecting families from hundreds – and soon thousands – of devastating diseases."

Field joins GenePeeks from Foundation Medicine, where he served as Vice President of Sales and Client Services, responsible for building, managing and leading the company's sales, sales operations, and client services organizations. Field played an instrumental role in developing and executing the company's commercial strategy and tactical launch plan for its comprehensive genomic profiling services.  Under Field's leadership, Foundation Medicine experienced unprecedented physician adoption of its technology and corresponding sales and revenue.  

Field is an industry leader with more than 20 years of experience with both large biopharma companies as well as entrepreneurial enterprises. Prior to Foundation Medicine, Field was Vice President of Strategic and Corporate Accounts at Caris Life Sciences where he launched the Oncology molecular diagnostics division and played a key role in growing the company from zero revenue to over $60 million in annual revenues in less than four years.  In addition, Field has helped to build several other disruptive, high-growth companies, including Astra Merck (now AstraZeneca) and AdvancePCS (now CVS Health).

 About GenePeeks

GenePeeks is a genetic information company focused on identifying inherited disease risk in future generations.  GenePeeks' patented technology digitally combines the genetic information of two potential parents, simulating the complex genetic interactions that occur naturally in human reproduction.  The company's proprietary platform creates and analyzes thousands of Virtual Progeny to uncover disease risk that cannot be seen with alternative screening tools. 

Using its patented platform, GenePeeks has developed a safe, non-invasive process for helping sperm and egg bank clients avoid donor matches that carry a high risk of passing on severe pediatric diseases. GenePeeks is now developing services for any family planning a pregnancy and using its expertise to conduct research to advance understanding of genetic disease and the effectiveness of pre-pregnancy risk prediction.

GenePeeks was founded by CEO Anne Morriss and Lee Silver, Ph.D., Professor of Molecular Biology at Princeton University, to help families protect their future children from serious diseases. The company's Executive Chair is Mara Aspinall, former CEO of Ventana Health Systems and former President of Genzyme Genetics. GenePeeks is privately held by Lifeprint Group, with offices in New York, NY and Cambridge, MA.  For more information, visit www.genepeeks.com.

Suggested Articles

A new clinical hold is the latest setback for Solid Biosciences and the development of its gene therapy for Duchenne muscular dystrophy.

VBI's Sci-B-Vac protected twice as many people than GSK's Engerix-B did after the second dose.

The notice comes weeks after Amgen revealed it was retreating from its East Coast neuroscience operations.